Background: Obesity is associated with better outcomes in diseases like myocardial infarction and heart failure, a phenomenon known as obesity paradox. However, the effect of obesity on healthcare outcomes after admission for diabetic ketoacidosis (DKA) has not been well characterized. Objective: We aimed to explore the impact of obesity and morbid obesity on outcomes in patients hospitalized with DKA. Methods: The National Inpatient Sample database for the year 2016 was queried. All admissions with a principal diagnosis of DKA were identified. Obesity (BMI 30-40 kg/m2) and morbid obesity (BMI >40 Kg/m2) were identified using their appropriate validated ICD-10 codes. Statistical analysis was performed using STATA. The Odds ratio adjusted for age and gender was calculated for obesity and morbid obesity respectively. Results: The study included 210,455 hospitalizations with a principal diagnosis of DKA. Out of these, 19,341 (9.19%) were obese and 7,640 (3.63%) were morbidly obese. Obese DKA patients had a longer length of stay (3.79 vs. 3.14 days, p<0.001) and higher hospitalization costs ($34,643 vs. $28,976; p<0.001) compared to their non-obese counterparts. There was no significant difference in the adjusted in-hospital mortality rates in DKA patients with and without obesity (0.52% vs. 0.38%, adjusted odds ratio 1.25, p=0.34). However, DKA patients who were morbidly obese had increased mortality compared to those without morbid obesity (0.72% vs. 0.38%, adjusted odds ratio 1.85, p=0.04). Conclusion: DKA patients with obesity have a longer length of stay and higher hospitalization costs, but similar inpatient mortality rates compared to those without obesity. Morbid obesity is associated with increased mortality in DKA patients. Disclosure M. Mudgal: None. A. Goel: None.
Objective: Familial partial lipodystrophy (FPLD) syndromes are rare and characterized by variable loss of adipose tissue in some areas of the body with excess deposition of fat in other areas, and complex metabolic derangements. We present a patient who had a new pathogenic variant identified in the PPARG gene that causes familial partial lipodystrophy type 3. Clinical case: A 48-year old Caucasian female was referred to the Endocrinology department for management of her type 2 diabetes mellitus. Her glycated hemoglobin was 12.1% and triglycerides were 2343 mg/dl. She was diagnosed with type 2 diabetes mellitus in the third decade of life. The patient had extreme insulin resistance with diabetic triopathy. She had a history of severe hypertriglyceridemia that lead to 3 episodes of pancreatitis. Family history was significant for hypertriglyceridemia in her father and a paternal uncle, both of whom died of hemorrhagic pancreatitis. Examination revealed a cushingoid appearance with facial, neck and truncal obesity and loss of peripheral fat on the buttocks, thighs and forearms. Her gastrocnemii appeared prominent. She had normal thyroid function and a normal 1 mg dexamethasone suppression test. Genetic testing revealed a new pathogenic heterozygous variant in the PPARG gene (c.1164del) that produces a premature stop codon (consistent with FPLD type 3). The patient was treated with Insulin Glargine-U300, Aspart and Pioglitazone. Three months after diagnosis, the patient passed away from myocardial infarction. Discussion: FPLD type 3 is a very rare type of autosomal dominant FPLD, reported in about 30 individuals worldwide per National Organization for Rare Disorders (NORD). It is resulted from mutation of PPARG gene, which encodes PPAR-gamma nuclear transcription factor. PPAR-gamma is a regulator of adipocyte differentiation. Loss of PPARG function leads to peripheral fat loss which primarily involves the gluteal region, calves and forearms with deposition of fat on the face, neck, and truncal areas. Metabolic complications include hypertriglyceridemia, insulin resistant diabetes, hypertension, hepatic steatosis, and pancreatitis. Management includes a calorie-restricted diet, exercise and pharmacotherapy. Conclusion: Recognition of the clinical features of FPLD including atypical fat distribution, hypertriglyceridemia, recurrent pancreatitis and severe insulin resistance can lead to early diagnosis and intervention which may reduce mortality in FPLD patients. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.